Bayer receives EU approval for its hemophilia A treatment Jivi ® (for specialized target groups only)

The safety and efficacy profile of Jivi has been demonstrated in more than five years of clinical studies / Prophylaxis with Jivi enables sustained factor VIII concentrations in the blood over time
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news